ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mosunetuzumab

Also written as “Mosunetuzumab”, “Mosunetuzumab (IV)” and “Mosunetuzumab (SC)”.

Its studies are mostly in Lymphoma, Follicular · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lupus Nephritis, led by 2 companies.

Drug pageMosunetuzumab: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 13, 202114 company-led studies, 7 open or runningNext primary completion: Jul 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche137 open or runningphase 3since Jan 13, 2021Jul 14, 2015Jul 31, 2027phase 2 · NCT05207670
Ipsenits history only10 open or runningphase 2since Dec 29, 2021Dec 29, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2015First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT02500407 · 713 enrolled · United States, Australia, Canada and more
  2. Jun 9, 2017Named mosunetuzumabINNProposed as its International Nonproprietary Name in WHO's List 117
  3. Sep 10, 20183 phase 2 studiesNCT03671018, NCT03677154, NCT03677141
  4. Jan 27, 2020Phase 2 study in Lymphoma, FollicularNCT04246086 · 237 enrolled · United States, China, France and more
  5. Mar 17, 2020Phase 1 study in Lymphoma, B-CellNCT04313608 · 23 enrolled · Australia
  6. Jan 13, 2021Phase 3 study in RecurrenceNCT04712097 · 478 enrolled · United States, Australia, Brazil and more
  7. Oct 12, 2021Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05091424 · 332 planned · United States, Australia, China and more
  8. Dec 6, 2021Phase 3 study in Lymphoma, Non-HodgkinNCT05171647 · 208 enrolled · United States, Argentina, Brazil and more
  9. Dec 10, 2021Phase 1 study in Lupus Erythematosus, SystemicNCT05155345 · 15 enrolled · United States, Moldova, Republic of, Poland
  10. Dec 15, 2021Phase 2 study in Lymphoma, Non-HodgkinNCT05207670 · 320 enrolled · United States
  11. Mar 31, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05315713 · 8 enrolled · United States, Australia, Belgium and more
  12. Feb 2, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07598396 · 30 planned · Argentina, Brazil, Colombia and more
  13. Nov 16, 2026Primary completion moved from 2028-02-28 to 2028-08-11Date moved laterphase 2 · +5 months · NCT07598396

Ahead

  1. Oct 1, 2027Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT05207670
  2. Aug 11, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07598396
  3. Sep 6, 2030Primary completion: phase 2 study in Lymphoma, FollicularNCT04246086
  4. Feb 10, 2031Primary completion: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05091424

TargetBeta

CD3E →MS4A1 →read by rule
“T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
GSK5926371GlaxoSmithKlinephase 22
REGN9220ruleRegeneron Pharmaceuticalsphase 21
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 13

Studies

All 13 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07598396Lupus Erythematosus, Systemic · Argentina, Brazil, Colombia and more2RecruitingAug 11, 202830
NCT05315713Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more2TerminatedJul 19, 20238
NCT05207670Lymphoma, Non-Hodgkin · United States2Active, not recruitingOct 1, 2027320
NCT05155345Lupus Erythematosus, Systemic · United States, Moldova, Republic of, Poland1CompletedDec 17, 202415
NCT05171647Lymphoma, Non-Hodgkin · United States, Argentina, Brazil and more3Active, not recruitingFeb 17, 2025208
NCT05091424Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, China and more1RecruitingFeb 10, 2031332
NCT04712097Recurrence · United States, Australia, Brazil and more3Active, not recruitingJun 3, 2026478
NCT04313608Lymphoma, B-Cell · Australia1CompletedOct 26, 202123
NCT04246086Lymphoma, Follicular · United States, China, France and more2Active, not recruitingSep 6, 2030237
NCT03677154Lymphoma, Large B-Cell, Diffuse · United States, Israel, Poland and more2CompletedAug 7, 2025188
NCT03677141Lymphoma, B-Cell · United States, Austria, France and more2CompletedOct 12, 2023117
NCT03671018Lymphoma, B-Cell · United States, Belgium, Canada and more2Active, not recruitingJan 30, 2024422
NCT02500407Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Canada and more2CompletedMay 21, 2024713

How it is read

Names in the registry

  • “Mosunetuzumab”, 8 entries
  • “Mosunetuzumab (IV)”, 2 entries
  • “Mosunetuzumab (SC)”, 2 entries
  • “Mosunetuzumab (Cohorts A-C)”, 1 entry
  • “Mosunetuzumab (Cohorts D-E)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.